Apellis eyes first FDA approval for treatment of a rare vision disorder

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES Apellis Pharma eyes a shot at getting first FDA approval in rare vision disorder Apellis Pharmaceuticals has additional clinical data that show its drug having an effect on geographic atrophy, a rare vision-loss disorder with no FDA-approved treatment. The biotech plans to include the latest results in a new drug application being readied for submission in coming months. Sponsored Content 3D Printed Medical Devices for Precision Surgery Webinar From Formlabs and MedCity News Additive manufacturing, or 3D printing, has steadily become more mainstream in the medical device sector because of its ability to enable cost-effective, patient-centered device development, particularly in the fields of orthopedic, spine, maxillofacial, and pediatric surgery. This webinar on April 6th will have perspectives from healthcare, the medical device sector, and the FDA to discuss how each are using 3D printing, the applications they are leveraging it for, how they can produce devices such as surgical tools more economically, the regulatory challenges they face, and how they can collaborate more effectively. Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy By Stephanie Baum Monday, March 21, 2022 7:30 AM AnHeart Therapeutics is developing a pipeline of precision oncology therapeutics. Chief Business Officer and Co-founder Lihua Zheng provided an overview of company's strategy in response to emailed questions. Read more » BMS nabs FDA nod for first drug in new class of cancer immunotherapies By Frank Vinluan Monday, March 21, 2022 6:00 AM Bristol Myers Squibb's Opdualag has been approved by the FDA, a first for a drug that goes after a new cancer target called LAG-3. The drug is approved for advanced melanoma as part of a combination treatment that includes the already approved BMS cancer immunotherapy Opdivo. Read more » The real power of data: Leveling the playing field in healthcare By Dr. Summerpal Kahlon Sunday, March 20, 2022 12:00 PM As we work to engage underserved communities in proactive, value-based medical treatment, we need to find ways to provide more granular data that accurately and precisely reflects the communities we serve. There is no more pressing issue than the advancement of care equity in a country so rife with disparities. Read more » MedCity Pivot Podcast: How Jonathan Bush wants to provide an operating system for a universal patient record By Arundhati Parmar Sunday, March 20, 2022 11:00 AM In this episode of the MedCity Pivot Podcast, Jonathan Bush talks about his latest venture – Zus Health – through which he wants to help digital health companies share data to create a universal patient off of which new products can be created to serve payers, providers and others with the ultimate goal of improving patient outcomes. Read more » When is it safe to discontinue TKI therapy in people with chronic myeloid leukemia? By Dr. Ehab Atallah Sunday, March 20, 2022 10:30 AM Some patients reach a point where ongoing TKI therapy can cause more harm than good. New data can simplify the decision to discontinue treatment. Read more » Crafting the next-generation value creation playbook in healthcare private equity By Todd Fitz and Eric Mayeda Sunday, March 20, 2022 9:00 AM While the pandemic has disrupted demand for certain healthcare sectors, it has accelerated innovation and provided an opportunity for investment in other areas. In particular, there's been rapid growth in virtual and home-based care delivery, along with the adoption of technology platforms. Read more » Apellis Pharma eyes a shot at getting first FDA approval in rare vision disorder By Frank Vinluan Sunday, March 20, 2022 8:11 AM Apellis Pharmaceuticals has additional clinical data that show its drug having an effect on geographic atrophy, a rare vision-loss disorder with no FDA-approved treatment. The biotech plans to include the latest results in a new drug application being readied for submission in coming months. Read more » Moving Beyond RPM to Remote Care Automation KLAS Research takes a closer look into the automated remote care platforms to discover how Robotic Process Automation (RPA) is impacting healthcare. Download this FREE report to learn more! MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails